IMP: Imexpharm Corporation - Summary | Jitta

Imexpharm Corporation

VNM:IMP

Price
₫50,800.00
Loss Chance
44.6%
6.11JITTA SCORE
42.98%Over Jitta Line
Jitta Ranking
184 / 622
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (65)
Recent Business Performance (91)
Financial Strength (79)
Return to Shareholders (51)
Competitive Advantage (65)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Operating MarginExpansion
Debt LevelLow Long Term Debt
Dividend PayoutEvery year
Interest Coverage RatioVery Good
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
6.11
42.98%
4.34
205.69%
3.94
171.55%
Pharmaceuticals
5.90
74.70%
4.60
133.75%
3.71
> 1,000%
COMPANY DESCRIPTION
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lanh, Vietnam. As of April 29, 2026, Imexpharm Corporation operates as a subsidiary of Livzon Pharmaceutical Group Inc..